Annual Drug Patent Expirations for NUCYNTA+ER
Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. It is available from two suppliers. There are eight patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for NUCYNTA ER.
This drug has two hundred and sixty-nine patent family members in thirty-seven countries.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. Two suppliers are listed for this compound. Additional details are available on the tapentadol hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
